Literature DB >> 27138468

Distribution of Biopsy-Proven Presumed Primary Glomerulonephropathies in 2000-2011 Among a Racially and Ethnically Diverse US Population.

John J Sim1, Michael Batech2, Aviv Hever3, Teresa N Harrison2, Taurino Avelar4, Michael H Kanter5, Steven J Jacobsen2.   

Abstract

BACKGROUND: The incidence and distribution of primary glomerulonephropathies vary throughout the world and by race and ethnicity. We sought to evaluate the distribution of primary glomerulonephropathies among a large racially and ethnically diverse population of the United States. STUDY
DESIGN: Case series from January 1, 2000, through December 31, 2011. SETTING & PARTICIPANTS: Adults (aged ≥ 18 years) of an integrated health system who underwent native kidney biopsy and had kidney biopsy findings demonstrating focal segmental glomerulosclerosis (FSGS), membranous glomerulonephritis (MGN), minimal change disease (MCD), immunoglobulin A nephropathy (IgAN), and other. OUTCOMES: Rates and characteristics of the most common primary glomerulonephropathies overall and by race and ethnicity.
RESULTS: 2,501 patients with primary glomerulonephropathy were identified, with a mean age 50.6 years, 45.7% women, 36.1% Hispanics, 31.2% non-Hispanic whites, 17.4% blacks, and 12.4% Asians. FSGS was the most common glomerulonephropathy (38.9%) across all race and ethnic groups, followed by MGN (12.7%), MCD (11.0%), IgAN (10.2%), and other (27.3%). The FSGS category had the greatest proportion of blacks, and patients with FSGS had the highest rate of poverty. IgAN was the second most common glomerulonephropathy among Asians (28.6%), whereas it was 1.2% among blacks. Patients with MGN presented with the highest proteinuria (protein excretion, 8.3g) whereas patients with FSGS had the highest creatinine levels (2.6mg/dL). Overall glomerulonephropathy rates increased annually in our 12-year observation period, driven by FSGS (2.7 cases/100,000) and IgAN (0.7 cases/100,000). MGN and MCD rates remained flat. LIMITATIONS: Missing data for urine albumin and sediment, indication bias in performing kidney biopsies, and inexact classification of primary versus secondary disease.
CONCLUSIONS: Among a racially and ethnically diverse cohort from a single geographical area and similar environment, FSGS was the most common glomerulonephropathy, but there was variability of other glomerulonephropathies based on race and ethnicity.
Copyright © 2016 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  IgA nephropathy (IgAN); Primary glomerulonephropathy; case series; epidemiology; focal segmental glomerulosclerosis (FSGS); glomerulonephritis; kidney biopsy; membranous glomerulonephritis (MGN); minimal change disease (MCD); nephrotic syndrome; race/ethnic predilection

Mesh:

Year:  2016        PMID: 27138468     DOI: 10.1053/j.ajkd.2016.03.416

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  31 in total

1.  Temporal Trends in the Epidemiology of Biopsy-Proven Glomerular Diseases: An Alarming Increase in Diabetic Glomerulosclerosis.

Authors:  Jean Hou; Mark Haas
Journal:  Clin J Am Soc Nephrol       Date:  2017-03-21       Impact factor: 8.237

2.  Characteristics of patients diagnosed with renal vein thrombosis and glomerulopathy: a case series.

Authors:  Oliver Ross; Andrew Pourmoussa; Michael Batech; John J Sim
Journal:  Int Urol Nephrol       Date:  2016-10-28       Impact factor: 2.370

Review 3.  Focal Segmental Glomerulosclerosis.

Authors:  Avi Z Rosenberg; Jeffrey B Kopp
Journal:  Clin J Am Soc Nephrol       Date:  2017-02-27       Impact factor: 8.237

4.  End-Stage Renal Disease Outcomes among the Kaiser Permanente Southern California Creatinine Safety Program (Creatinine SureNet): Opportunities to Reflect and Improve.

Authors:  John J Sim; Michael Batech; Kim N Danforth; Mark P Rutkowski; Steven J Jacobsen; Michael H Kanter
Journal:  Perm J       Date:  2017

5.  The Spectrum of Biopsy-Proven Glomerular Diseases among Children in China: A National, Cross-Sectional Survey.

Authors:  Sheng Nie; Wenjuan He; Ting Huang; Diankun Liu; Guobao Wang; Jian Geng; Nan Chen; Gang Xu; Ping Zhang; Yang Luo; Jing Nie; Xin Xu; Fan Fan Hou
Journal:  Clin J Am Soc Nephrol       Date:  2018-06-18       Impact factor: 8.237

6.  Temporal and Demographic Trends in Glomerular Disease Epidemiology in the Southeastern United States, 1986-2015.

Authors:  Michelle M O'Shaughnessy; Susan L Hogan; Caroline J Poulton; Ronald J Falk; Harsharan K Singh; Volker Nickeleit; J Charles Jennette
Journal:  Clin J Am Soc Nephrol       Date:  2017-03-21       Impact factor: 8.237

7.  Clinical features and pathogenesis of membranoproliferative glomerulonephritis: a nationwide analysis of the Japan renal biopsy registry from 2007 to 2015.

Authors:  Naoki Nakagawa; Naoyuki Hasebe; Motoshi Hattori; Michio Nagata; Hitoshi Yokoyama; Hiroshi Sato; Hitoshi Sugiyama; Akira Shimizu; Yoshitaka Isaka; Shoichi Maruyama; Ichiei Narita
Journal:  Clin Exp Nephrol       Date:  2017-12-06       Impact factor: 2.801

8.  Identifying Patients with Rare Disease Using Electronic Health Record Data: The Kaiser Permanente Southern California Membranous Nephropathy Cohort.

Authors:  Amy Z Sun; Yu-Hsiang Shu; Teresa N Harrison; Aviv Hever; Steven J Jacobsen; Michelle M O'Shaughnessy; John J Sim
Journal:  Perm J       Date:  2020-02-07

9.  The Incidence of Primary vs Secondary Focal Segmental Glomerulosclerosis: A Clinicopathologic Study.

Authors:  Musab S Hommos; An S De Vriese; Mariam P Alexander; Sanjeev Sethi; Lisa Vaughan; Ladan Zand; Kharmen Bharucha; Nicola Lepori; Andrew D Rule; Fernando C Fervenza
Journal:  Mayo Clin Proc       Date:  2017-10-27       Impact factor: 7.616

10.  Kidney Histopathology and Prediction of Kidney Failure: A Retrospective Cohort Study.

Authors:  Michael T Eadon; Tae-Hwi Schwantes-An; Carrie L Phillips; Anna R Roberts; Colin V Greene; Ayman Hallab; Kyle J Hart; Sarah N Lipp; Claudio Perez-Ledezma; Khawaja O Omar; Katherine J Kelly; Sharon M Moe; Pierre C Dagher; Tarek M El-Achkar; Ranjani N Moorthi
Journal:  Am J Kidney Dis       Date:  2020-04-24       Impact factor: 8.860

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.